Outlook Therapeutics has entered into an underwriting agreement for a public offering of common stock and accompanying warrants, expecting to raise approximately $55.0 million in gross proceeds. The offering, priced at $0.99 per share and accompanying warrant, is scheduled to close on or about August 14, 2026.
Key Details
- Offering Size: The offering consists of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares.
- Warrant Terms: Each warrant is immediately exercisable at a price of $1.10 per share and will expire five years from the date of issuance.
- Underwriter Option: Underwriters have a 30-day option to purchase up to 8,333,333 additional shares and/or warrants. The underwriters exercised this option for warrants to purchase an additional 8,333,333 shares on August 12, 2026.
- Insider Participation: The company's largest stockholder, GMS Ventures, along with the CEO and CFO, purchased shares and warrants in the offering.